Skip to content
City AM
Main navigation
Download free app
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Tech
      • Banking
      • FTSE 100 Live
      • Retail
      • Insurance
      • Legal
      • Property
      • Transport
      • Markets
    • From our partners
      • AON
      • Bayes Business School
      • City of London BIDs
      • Central London Alliance CIC
      • Destination City
      • Halkin
      • Olympia
      • Inside Saudi
      • Tottenham Hotspur Stadium
      • Santander X
      • YEAR SIX Dividend
    • Featured

      Mahmood unveils refugee sponsorship route as asylum bill faces Labour test

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
      • The Punter
    • From our partners
      • The Morning Briefing: SBS x City AM
      • Aramco Team Series
      • LIV Golf
    • Featured

      World Cup: How brands will activate as the knockouts begin

      Morocco v Haiti: Group C - FIFA World Cup 2026

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • City AM Puzzles
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      Exclusive: Richard Caring in talks to buy City icon 1 Lombard Street

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Events
  • Newsletters
  • Latest Paper

medicine

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal

    The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a long-running legal battle over allegations of excessive pricing, overturning a previous decision by the Tribunal. The court said the Competition Appeal Tribunal (CAT), was “wrong to set aside the [Competition and Market’s Authority’s] decision” in relation to [...]

    Hikma reported a jump in profit for 2024
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma

    Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]

    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • Haleon takes hit from ‘weak cold and flu season’ but Sensodyne shines

    Retail

    After being spun out from GSK in the biggest London IPO in decades, City analyst are looking for more from the emblematic FTSE 100 consumer healthcare powerhouse with roots in a Lombard Street apothecary shop Fewer sniffles during the winter have sent a chill through sales volumes at Haleon, the FTSE 100 over-the-counter remedy maker. [...]

    Haleon has reported its 2024 results
  • Reckitt: Durex condom maker strips back costs as profit inches up

    March 5, 2026

    Consumer goods giant Reckitt posted a bump to revenue in the last financial year as its cost overhaul strategy to focus on specific divisions ramped up. The blue-chip firm – which owns a massive portfolio of brands including Dettol, Durex, Lysol, Finish, Vanish, and Gaviscon – recorded a 5.2 per cent increase in revenue, driven [...]

  • Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade

    November 12, 2024

    Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]

  • GSK: Zantac settlements hit profit but guidance unchanged

    October 30, 2024

    Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose [...]

  • Advanced Medical Solutions: Strong US sales boosts revenue for wound-closure tech firm

    July 15, 2024

    Advanced Medical Solutions (AMS) has announced a 10 per cent revenue hike for the first half of 2024 after sales for wound-closure tech in the United States took off. The company, which develops and manufactures tissue-healing technology, announced first-half revenue of £68m. Based on these numbers, the firm said it expected to report adjusted profit [...]

  • Losses widen for Cohens Chemist amid funding uncertainty

    May 23, 2024

    The company behind Cohens Chemist almost doubled its losses this year, with product shortages and inflation continuing to put pressure on the group. 

  • Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions

    May 21, 2024

    Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.

  • When the drugs don’t work: How the UK became addicted to antidepressants

    May 14, 2024

    Almost one in four adults are being prescribed antidepressants, but they are not as effective as was once believed, writes Lucy Kenningham

Posts pagination

  • Page 1
  • Page 2
  • Next

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Clarkson’s Farm and why businesses must stop blaming the weather

Subscribe

Subscribe to the City AM newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • Got a story?
  • About City AM
  • Careers
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Politics
  • Opinion
  • Life&Style
  • Personal Finance
  • City AM Events
  • City Winners
  • The Punter
  • Casino
  • City AM Puzzles

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
  • Newsletters
  • Advertising
  • About
  • Licensing
Copyright 2026 City AM Limited